Politics

Q&A: BIO's Jim Greenwood

Q&A: BIO's Jim Greenwood

By

BIO chief Jim Greenwood talks policy priorities and previews the group's International Convention, now underway in Chicago.

Obama budget would bleed pharmas

By

The White House released its proposed budget for the 2014 fiscal year this morning, and while it gives a modest boost to Health and Human Services, it also seeks to extract more cost savings from pharmas.

Sequester cuts could snarl approvals for years

Sequester cuts could snarl approvals for years

By

With sequester cuts taking effect and no sign of a deal to end them in sight, FDA stands to lose 5% of its 2013 budget—though coming five months into the Federal fiscal year, it will feel more like 9%—and while the agency has said it has no plans at present for layoffs, it's certain the approvals process will slow as the agency absorbs the loss.

Congress loses a healthcare mover, and pharma an unlikely ally on IPAB

Congress loses a healthcare mover, and pharma an unlikely ally on IPAB

By

The November elections were arguably the most important for healthcare policy in 40 years, cementing, as they did, the Affordable Care Act by awarding President Obama a second term. But with all eyes glued to the drama at the top of the ticket, many missed a major Congressional upset that could have big implications for healthcare policy.

The year ahead: A Capitol bit of crystal ball-gazing

From FDA and pharma, to Caronia and off-label communication, three healthcare policy experts offer their take on what 2013 holds in store.

Full steam ahead for Obamacare, but gridlock isn't going anywhere

Full steam ahead for Obamacare, but gridlock isn't going anywhere

By

President Obama has cemented his greatest legislative achievement, the Affordable Care Act, but the status quo should prove anything but boring, with implementation of the law sure to mean more political fireworks

Voting with their wallets, pharmas say no thanks to change

Voting with their wallets, pharmas say no thanks to change

By

Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?

Docs' presidential preferences follow practice type

Docs' presidential preferences follow practice type

By

Solo practitioners favor Mitt Romney over Barack Obama by a two-to-one ratio, a survey finds, suggesting that changes in reimbursement driven by Obamacare are driving physicians' presidential preferences.

Email Newsletters